4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $4350 | -$9M | 56.8% | -192013.1% | -$7M | — | $1M |
| 2024 | $18600 | -$7M | 67.3% | -33902.0% | -$6M | — | $6M |
| 2023 | $5150 | -$6M | 45.7% | -118698.3% | -$6M | — | $2M |
| 2022 | $14373 | -$5M | 45.1% | -32765.6% | -$4M | — | $918260 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Jan '26 | $0 | -$2M | — | — | — | — | $3M |
| Oct '25 | $2419 | -$2M | 58.3% | -85713.2% | — | — | $2M |
| Jul '25 | $1900 | -$2M | 60.0% | -98637.8% | — | — | $3M |
| Apr '25 | — | -$2M | — | — | -$2M | — | $1M |
| Jan '25 | $0 | -$3M | — | — | -$2M | — | $3M |
| Oct '24 | — | -$2M | — | — | — | — | $4M |
| Jul '24 | — | -$2M | — | — | — | — | $4M |
| Apr '24 | $0 | -$2M | — | — | -$2M | — | $6M |
| Jan '24 | $14700 | -$2M | 69.0% | -10376.7% | -$2M | — | $7M |
| Oct '23 | $3900 | -$2M | 61.0% | -40254.9% | -$990139 | — | $100144 |
| Jul '23 | — | -$1M | — | — | -$1M | — | $575654 |
| Apr '23 | $0 | -$2M | — | — | -$2M | — | $2M |
| Jan '23 | $1950 | -$1M | 61.0% | -67143.7% | -$1M | — | $2M |
| Oct '22 | $0 | -$2M | — | — | -$1M | — | $3M |
| Jul '22 | $3200 | -$2M | 36.4% | -44690.5% | -$2M | — | $4M |
| Apr '22 | $4149 | -$2M | 69.1% | -47669.6% | -$1M | — | $918260 |
| Jan '22 | $2740 | -$1M | 68.8% | -40156.5% | -$966278 | — | — |
| Oct '21 | $0 | -$1M | — | — | — | — | — |
| Jul '21 | $7484 | -$501851 | 23.1% | -9011.8% | — | — | — |
How the market has priced HSCS against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 3 years, HeartSciences Inc.'s revenue has declined 32.9% per year. These are computed facts, not advice.
As of FY2025, HeartSciences Inc. reported — of total debt against $1M of cash; operating income covered interest expense -16.7×.
In FY2025, gross margin was 56.8%, operating margin -192013.1%, and net margin -201499.5%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.